| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
|
Machiels, J.-P.
|
|
|
29 |
4 |
p. 985-991
|
artikel
|
| 2 |
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
|
Guibert, N.
|
|
|
29 |
4 |
p. 1049-1055
|
artikel
|
| 3 |
A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma
|
Li, X.C.
|
|
|
29 |
4 |
p. 938-944
|
artikel
|
| 4 |
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
|
Banerjee, S.
|
|
|
29 |
4 |
p. 917-923
|
artikel
|
| 5 |
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
|
Fushimi, C.
|
|
|
29 |
4 |
p. 979-984
|
artikel
|
| 6 |
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
|
Arnold, D.
|
|
|
29 |
4 |
p. 835-856
|
artikel
|
| 7 |
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications
|
Laroche-Clary, A.
|
|
|
29 |
4 |
p. 1023-1029
|
artikel
|
| 8 |
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
|
Buisseret, L.
|
|
|
29 |
4 |
p. 1056-1062
|
artikel
|
| 9 |
Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial
|
Sobhani, I.
|
|
|
29 |
4 |
p. 931-937
|
artikel
|
| 10 |
Computational prediction of neoantigens: do we need more data or new approaches?
|
Eklund, A.C.
|
|
|
29 |
4 |
p. 799-801
|
artikel
|
| 11 |
Corrigendum: mdw197, mdw434 and mdw695
|
|
|
|
29 |
4 |
p. 1075
|
artikel
|
| 12 |
Crizotinib: from discovery to accelerated development to front-line treatment
|
Blackhall, F.
|
|
|
29 |
4 |
p. 1073
|
artikel
|
| 13 |
Developing androgen receptor targeting for salivary gland cancers
|
Ho, A.L.
|
|
|
29 |
4 |
p. 792-794
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
29 |
4 |
p. ii-iii
|
artikel
|
| 15 |
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
|
Aspeslagh, S.
|
|
|
29 |
4 |
p. 812-824
|
artikel
|
| 16 |
ESMO-MCBS v1.1: statistical and patient-relevant shortcomings
|
Emprechtinger, R.
|
|
|
29 |
4 |
p. 1070-1071
|
artikel
|
| 17 |
ESR1 and endocrine therapy resistance: more than just mutations
|
Piscuoglio, S.
|
|
|
29 |
4 |
p. 787-789
|
artikel
|
| 18 |
European cancer mortality predictions for the year 2018 with focus on colorectal cancer
|
Malvezzi, M.
|
|
|
29 |
4 |
p. 1016-1022
|
artikel
|
| 19 |
EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity
|
Hofheinz, R.-D.
|
|
|
29 |
4 |
p. 1010-1015
|
artikel
|
| 20 |
Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries
|
Oskay-Özcelik, G.
|
|
|
29 |
4 |
p. 910-916
|
artikel
|
| 21 |
Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck
|
Awan, M.J.
|
|
|
29 |
4 |
p. 998-1003
|
artikel
|
| 22 |
Funding sources of practice-changing trials
|
Dogan, S.
|
|
|
29 |
4 |
p. 1063-1065
|
artikel
|
| 23 |
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients
|
Raponi, S.
|
|
|
29 |
4 |
p. 966-972
|
artikel
|
| 24 |
Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC
|
Vanden Bempt, I.
|
|
|
29 |
4 |
p. 789-791
|
artikel
|
| 25 |
Genomic medicine France 2025
|
Lethimonnier, F.
|
|
|
29 |
4 |
p. 783-784
|
artikel
|
| 26 |
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex—what we know and what we need to learn
|
Özdemir, B.C.
|
|
|
29 |
4 |
p. 1067
|
artikel
|
| 27 |
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
|
Kim, S.T.
|
|
|
29 |
4 |
p. 1037-1048
|
artikel
|
| 28 |
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
|
Rugo, H.S.
|
|
|
29 |
4 |
p. 888-894
|
artikel
|
| 29 |
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
|
Röllig, C.
|
|
|
29 |
4 |
p. 973-978
|
artikel
|
| 30 |
Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project
|
Turnbull, C.
|
|
|
29 |
4 |
p. 784-787
|
artikel
|
| 31 |
Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses
|
Carr, P.R.
|
|
|
29 |
4 |
p. 825-834
|
artikel
|
| 32 |
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) †
|
|
|
|
29 |
4 |
p. 857-871
|
artikel
|
| 33 |
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
|
Adam, J.
|
|
|
29 |
4 |
p. 953-958
|
artikel
|
| 34 |
Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
|
Kim, S.
|
|
|
29 |
4 |
p. 1030-1036
|
artikel
|
| 35 |
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
|
Vokes, E.E.
|
|
|
29 |
4 |
p. 959-965
|
artikel
|
| 36 |
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer
|
Cortes, J.
|
|
|
29 |
4 |
p. 881-887
|
artikel
|
| 37 |
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
|
Birkbak, N.J.
|
|
|
29 |
4 |
p. 903-909
|
artikel
|
| 38 |
PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?
|
Lavolé, A.
|
|
|
29 |
4 |
p. 1065-1066
|
artikel
|
| 39 |
PD-1 blockade with nivolumab in endemic Kaposi sarcoma
|
Delyon, J.
|
|
|
29 |
4 |
p. 1067-1069
|
artikel
|
| 40 |
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
|
Tahara, M.
|
|
|
29 |
4 |
p. 1004-1009
|
artikel
|
| 41 |
Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN)
|
Vigneswara, V.
|
|
|
29 |
4 |
p. 794-796
|
artikel
|
| 42 |
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
|
Dell’Aquila, E.
|
|
|
29 |
4 |
p. 924-930
|
artikel
|
| 43 |
Recommendations for the clinical management of the elderly patient with malignant lymphoma
|
Specht, L.
|
|
|
29 |
4 |
p. 1069-1070
|
artikel
|
| 44 |
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
|
Hartmaier, R.J.
|
|
|
29 |
4 |
p. 872-880
|
artikel
|
| 45 |
Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701)
|
Kodaira, T.
|
|
|
29 |
4 |
p. 992-997
|
artikel
|
| 46 |
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
|
Musto, P.
|
|
|
29 |
4 |
p. 1074
|
artikel
|
| 47 |
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis
|
Trone, J.C.
|
|
|
29 |
4 |
p. 803-811
|
artikel
|
| 48 |
Surgery for patients with ‘lower grade’ glioma: putting assumptions, beliefs and convictions into perspective
|
Weller, M.
|
|
|
29 |
4 |
p. 1077
|
artikel
|
| 49 |
Table of Contents
|
|
|
|
29 |
4 |
p. iv-vii
|
artikel
|
| 50 |
Taking it in the chin: vitamin K1 for the prevention of acneiform rash
|
Lacouture, M.E.
|
|
|
29 |
4 |
p. 796-798
|
artikel
|
| 51 |
Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups
|
Adam, J.
|
|
|
29 |
4 |
p. 798-799
|
artikel
|
| 52 |
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
|
Aguiar Jr, P.N.
|
|
|
29 |
4 |
p. 1078
|
artikel
|
| 53 |
Time is up for PD-L1 testing standardization in lung cancer
|
Dacic, S.
|
|
|
29 |
4 |
p. 791-792
|
artikel
|
| 54 |
Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter
|
Klempner, S.J.
|
|
|
29 |
4 |
p. 801-802
|
artikel
|
| 55 |
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer
|
Janku, F.
|
|
|
29 |
4 |
p. 1076
|
artikel
|
| 56 |
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
|
Li, Y.S.
|
|
|
29 |
4 |
p. 945-952
|
artikel
|
| 57 |
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
|
Bareche, Y.
|
|
|
29 |
4 |
p. 895-902
|
artikel
|
| 58 |
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
|
Kadara, H.
|
|
|
29 |
4 |
p. 1072
|
artikel
|
Tijdschrift beschrijving